Lucy Therapeutics
John Ripple has held a variety of roles in the biotechnology industry since 2013. John started as the CEO of Exonics Therapeutics in 2017, and then became an Entrepreneur in Residence at Mass General Brigham Ventures the same year. In 2020, they became the Co-Founder of Mark Therapeutics Inc., and also took on the roles of Independent Director at BioEntre LLC and Lucy Therapeutics. In 2021, they became an Independent Director at Brave Bio, and a Strategic Advisor at MarvelBiome Inc. Currently, John is the Executive Chair at Praesidia Biotherapeutics, and the Owner of Ripple Biotech LLC.
John Ripple attended Bucknell University, where they earned a BS in Mechanical Engineering. John then went on to Harvard Business School, where they earned an MBA in General Management.
This person is not in the org chart
This person is not in any teams
Lucy Therapeutics
Lucy Therapeutics is offering a differentiated and novel approach to drug discovery by drugging targets associated with early disease pathogenesis. LucyTx’s unique approach recognizes that improvement of mitochondrial function early in disease will lead to disease modification as opposed to late-stage symptomatic treatments being pursued by many others. Mitochondrial improvement effects multiple downstream effectors that are essential to disease initiation and progression. Our targets have been validated as neuroprotective in multiple animal models. Key to our strategy is a novel dosing regimen which will mimic effects known to be protective for both neurological and cardiovascular events implicated in key CNS diseases. LucyTx proposes to focus on the orphan disease Rett Syndrome for a proof of concept; we will also explore applications of our technology to Parkinson’s and other CNS diseases.